Aligos Therapeutics (ALGS) announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 81,100 shares of the Company’s stock to newly hired employees on January 29, 2026, in connection with the commencement of employment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics provides update for Phase 2 study of pevifoscorvir sodium
- Aligos Therapeutics announces resignation of Chief Medical Officer Achneck
- Aligos Therapeutics management to meet virtually with Piper Sandler
- Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market
- Aligos Therapeutics appoints James Hassard as EVP, CCO